Page 141 - Eceptor News Today

Researchers demonstrated the inhalation of an ACE2 decoy receptor, sACE22.v2.4-IgG1, increases survival and ameliorates lung injury in K18-hACE2 transgenic mice.

Since the onset of the coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), scientists have been conducting extensive studies to understand various aspects of the virus. Researchers have stated that SARS-CoV-2 manifests several biological and clinical consequences of a superantigen

As the COVID-19 pandemic enters its third year, Northwestern Medicine scientists continue to help advance the understanding of the disease and its impact, from investigating antibody protection against COVID-19 reinfection to elevating women in academic research and highlighting racial and ethnic disparities in COVID-19 hospital mortality in Illinois.

An article has described the role of cannabidiol as a potential inhibitor of hyperinflammation in SARS-CoV-2 infection.

A new study assessed the molecular dynamics of potentially active natural phytochemicals to target the SARS-CoV-2 main protease.

A new approach from Penn Medicine researchers could cut the time it takes to alter patients' immune cells for infusion back into the body to find and attack cancer.

A new research paper published as an early release manuscript in the Nature Medicine journal compares the sensitivity of this strain as well as the earlier Delta and the newer BA.2 to therapeutic mAbs.

Taiho Pharmaceutical Obtains Approval to Manufacture and Market NK1 Receptor Antagonist Arokaris I.V. Infusion 235mg in Japan Tokyo, Japan, and Lugano, Switzerland March 28, 2022

Researchers evaluated the ability of RBD antibodies to bind to and neutralize SARS-CoV-2 Omicron variant.

Researchers discuss the results of a clinical trial to assess the efficacy and safety of IV sarilumab for the treatment of hospitalized COVID-19 patients.